A U.S.-based biotechnology company, Conceivable Life Sciences, has announced the birth of the world’s first baby conceived through an AI-powered, fully automated in vitro fertilization (IVF) process, marking a major milestone in reproductive technology. The company recently secured $50 million in new funding—equivalent to approximately 360 million RMB—to advance its mission of transforming fertility treatment through artificial intelligence and robotics. The baby, a healthy boy, was born to a couple in their 40s who had struggled with infertility for years. The man had severely impaired sperm motility, while the woman experienced irregular ovulation and had previously failed IVF attempts, producing only one mature egg. In this case, donor eggs were used to support conception. The groundbreaking procedure took place at Hope IVF Mexico, where Conceivable installed its proprietary AURA laboratory platform—a system combining AI algorithms with robotic precision. The process involved 115 automated steps across five eggs treated using the company’s fully digital intracytoplasmic sperm injection (ICSI) system, compared to three control eggs treated via traditional manual ICSI. The entire ICSI procedure, which normally consists of 23 steps, was executed remotely by operators in New York, over 3,700 kilometers away, via a digital interface. The AI system selected the most viable sperm based on morphological analysis and used laser technology to immobilize the sperm tail, improving accuracy during injection. Of the five eggs injected via automation, four achieved normal fertilization—matching the 3 out of 3 success rate in the manual control group. The company then used AI to evaluate embryo quality based on chromosomal appearance, selecting two high-potential embryos for transfer. One embryo failed to develop after implantation, but the second successfully implanted and led to a full-term pregnancy. The resulting baby, born after the transfer of a blastocyst developed through the automated system, is the first live birth from a nearly entirely AI-driven IVF process. The entire procedure was part of a pilot study overseen by a medical ethics review board. The research was published in the journal Reproductive BioMedicine Online in April 2025, providing detailed insights into the technical and clinical aspects of the breakthrough. Conceivable’s AURA platform automates over 200 steps in IVF, from culture dish preparation and sperm processing to egg selection, fertilization, and embryo culture. By standardizing procedures and minimizing human error, the system enhances consistency, reduces fatigue-related mistakes, and improves the precision of delicate operations. The platform’s intuitive interface also allows for remote monitoring and real-time control, enabling clinicians to oversee the process from anywhere. The company reports that its automated system achieves a 51% success rate in embryo development, with embryo quality comparable to that of naturally developing embryos in the womb. While the current process takes about 9 minutes and 56 seconds per egg—slightly longer than manual ICSI—Conceivable anticipates significant time reductions through ongoing optimization. Infertility affects about one in six people globally, according to the World Health Organization. IVF has evolved since the first successful case in 1978 by Robert Edwards and Patrick Steptoe. The development of ICSI in 1992 by Gianpiero Palermo revolutionized treatment for male infertility by enabling direct sperm injection into eggs. However, manual ICSI remains dependent on human skill and consistency, which can vary due to fatigue or distraction. Conceivable’s technology aims to eliminate these variables. The company is now recruiting 120 participants for a larger, randomized clinical trial to compare automated versus manual ICSI outcomes and assess real-world impact on pregnancy and birth rates. While automation currently increases costs, Conceivable expects prices to drop as the system scales and becomes standardized. The latest $50 million funding round was led by Singapore-based ARTIS Ventures, with additional investment from UK-based Stride.VC and U.S.-based ACME Ventures—firms that previously backed the company. The funds will support further development of AI-driven automation, system refinement, and broader clinical validation. This milestone represents a transformative leap toward fully autonomous IVF labs, potentially expanding access to high-quality fertility care and improving success rates worldwide.